Thursday, September 3, 2026 · Five AI analysts screened this index for stocks with the best shot at gaining +5% within 30 days
Optimistic Calm market · VIX 14.6
Momentum is broad-based, with energy majors and refiners, biotech/pharma names, and select mega-cap tech all showing 5-day and 30-day gains while trading within a few percent of their 52-week highs. Bonds rallied on dovish Fed commentary, adding a supportive macro tailwind for risk assets. Breadth of the rally supports a bullish near-term stance, though several high-flying momentum names (semiconductors, speculative tech) look overextended and were avoided.
Which of today's picks to actually take, and at what size, given what you are already holding. Each pick's own Suggested Allocation sizes it in isolation; this table applies the portfolio limits — at most 20 open positions and 60% of the portfolio committed in total. Run with --capital 25000 to see these sizes as order amounts rather than percentages.
| Rank | Stock | Action | Size | Entry → Target | Notes |
|---|---|---|---|---|---|
| #1 | BIIB | SKIP | — | $224.10 → $235.68 stop $205.05 |
Position cap reached — 106 of 20 slots in use. |
| #2 | HPQ | SKIP | — | $32.19 → $33.86 stop $29.10 |
Position cap reached — 106 of 20 slots in use. |
| #3 | JNJ | SKIP | — | $278.15 → $292.06 stop $261.46 |
Position cap reached — 106 of 20 slots in use. |
| #4 | DE | SKIP | — | $694.70 → $732.91 stop $639.12 |
Position cap reached — 106 of 20 slots in use. |
Already open: RJF (to Sep 4), NVDA (to Sep 5), SWK (to Sep 6), WAT (to Sep 9), LLY (to Sep 10), DRI (to Sep 11), DXCM (to Sep 11), BDX (to Sep 12), BLK (to Sep 12), EXPD (to Sep 13), FDX (to Sep 13), CPAY (to Sep 16) … and 94 more. Symbols you already hold were excluded from this run's candidates rather than re-picked.
Position-sizing guidance only — half-Kelly per pick, bounded by the limits above. Not personal investment advice.
Biogen develops treatments for neurological diseases like Alzheimer's and ALS. Shares have climbed steadily and are outperforming the market with healthy, not overheated, technical readings. The main risk is that biotech stocks can swing sharply on unexpected drug-trial or regulatory news.
Why the AI likes it
What could go wrong
Calibrated probability: 66% (raw model estimate: 74%) — adjusted using the accuracy of past resolved picks.
Trade math
Suggested allocation is half-Kelly sizing guidance capped at 10% — not personal investment advice.
What each AI analyst estimated
HP makes personal computers and printers. The stock has jumped sharply over the past month and continues to outperform the broader market. One caution flag: the recent price gains haven't been fully matched by rising trading volume, which can sometimes foreshadow a pause, so this is a slightly higher-risk pick within an otherwise strong group.
Why the AI likes it
What could go wrong
Calibrated probability: 66% (raw model estimate: 72%) — adjusted using the accuracy of past resolved picks.
Trade math
Suggested allocation is half-Kelly sizing guidance capped at 10% — not personal investment advice.
What each AI analyst estimated
Johnson & Johnson is a diversified healthcare giant spanning pharmaceuticals and medical devices. It's been climbing steadily and beating the broader market, and it also tends to move less violently than most other stocks, which means less potential downside if things don't go as planned. The main risk is a reversal if the market turns, plus the company's ongoing legal liabilities.
Why the AI likes it
What could go wrong
Calibrated probability: 66% (raw model estimate: 73%) — adjusted using the accuracy of past resolved picks.
Trade math
Suggested allocation is half-Kelly sizing guidance capped at 10% — not personal investment advice.
What each AI analyst estimated
Deere makes tractors and farm machinery. The stock has been on a strong upward run, outperforming the broader market, with healthy buying momentum that isn't yet stretched into overbought territory. The main risks are that gains could unwind in a market pullback, and recent heavy selling by company insiders is worth watching.
Why the AI likes it
What could go wrong
Calibrated probability: 66% (raw model estimate: 76%) — adjusted using the accuracy of past resolved picks.
Trade math
Suggested allocation is half-Kelly sizing guidance capped at 10% — not personal investment advice.
What each AI analyst estimated
This report identifies stocks with an AI-assessed probability of gaining +5% within 30 calendar days (target exit by October 3, 2026). Picks are ranked by how many independent AI agents agreed — more agreement means higher conviction. The guide below tells you exactly how to act on them.
Step-by-Step Action Plan
Position Sizing by Conviction Tier
Size each position according to the coloured border on its pick card. Cap your total exposure across all picks from this report at 25% of your overall trading budget.
| Agents Agreeing | What It Means | Max Allocation Per Pick |
|---|---|---|
| 5/5 | Highest conviction — all five independent analytical checks passed | Up to 10% |
| 4/5 | Very high conviction — four of five independent checks aligned | Up to 8% |
| 3/5 | High conviction — three agents independently agreed | Up to 6% |
| 2/5 | Moderate conviction — two agents independently agreed | Up to 4% |
| 1 Agent | Speculative — solo pick, admitted only at Very High confidence | Up to 2% |
The Three Exit Rules
A plain-English guide to every figure shown on each pick card — what it means, how it is calculated, and what a good or bad value looks like.
Scout scanned 503 S&P 500 constituents and short-listed 28 candidates for deep analysis by the five analysts. Here is what happened to each one.
Checks 30-day price history for every candidate before making any selection. Requires positive period return and positive 5-day momentum as mandatory gates. Ranks picks by proximity to their period high and adjusts probability based on volume. Uses news only to rule out major negative catalysts.
Searches earnings results, analyst upgrades, and revenue trends before checking price data. Requires at least one verifiable fundamental catalyst — earnings beat, analyst upgrade, or revenue acceleration — within the last 60 days. Favours stocks with strong fundamentals trading below recent highs (value entry).
Hunts for specific events within the last 21 days: FDA approvals, major contract wins, product launches, earnings surprises, or significant analyst upgrades. Requires a positive price reaction confirming the market is recognising the catalyst. Also scans for upcoming events that could drive further gains.
Maps the macroeconomic regime (risk-on / risk-off / neutral) and identifies sectors benefiting from current conditions before looking at individual stocks. Only selects stocks from macro-aligned sectors with confirmed sector tailwinds. Adjusts for interest rate sensitivity and geopolitical factors.
Reviews the final picks after all four analysts agree and actively challenges each bull thesis. Searches for bearish technical signals, negative news, insider selling, and elevated short interest that the agreeing agents may have underweighted. Produces evidence-based counter-arguments shown on each pick card.
Pure-quant analyst: no news, no narrative, only numbers. Identifies mean-reversion setups from RSI extremes (<35) with momentum turning, Bollinger squeeze breakouts, and multi-factor quant scores using RSI, MACD, OBV, short interest, and insider transaction data. Counterbalances narrative bias across the four analyst agents.